Biotech Values

[DewDiligence]

NIH’s own statement on the halted AIM-HIGH study (emphasis added):

http://public.nhlbi.nih.gov/newsroom/home/GetPressRelease.aspx?id=2792

The rationale for the AIM-HIGH study was based in part on a large number of observational studies that consistently showed that low HDL cholesterol increases the risk of cardiovascular events in men and women, independent of high LDL cholesterol.

In addition, previous small clinical studies showed that relatively high residual cardiovascular risk exists among patients with cardiovascular disease, low HDL cholesterol, and high triglycerides despite intensive management of LDL cholesterol.

However, efforts to find HDL-raising treatments that actually reduce this residual risk have thus far proved disappointing.

That’s why you run large, prospective, randomized trials to find out.